Combined Phacoemulsification and Intravitreal Dexamethasone Implant (Ozurdex ®) in Diabetic Patients with Coexisting Cataract and Diabetic Macular Edema.

CONCLUSION: Intravitreal slow-release dexamethasone implant combined with cataract surgery may be an effective approach on morphologic and functional outcomes for patients with cataract and diabetic macular edema for at least three months after surgery. PMID: 28884024 [PubMed]
Source: Journal of Ophthalmology - Category: Opthalmology Tags: J Ophthalmol Source Type: research